{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:10:07Z","timestamp":1791259807428,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Infliximab (IFX) is an immunosuppressive drug widely used for the treatment of patients with Beh\u00e7et\u2019s syndrome (BS) with severe or refractory organ involvements. The aim of this study was to evaluate IFX survival, clinical response and safety profile in a monocentric cohort of BS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with BS treated with IFX intravenously across a 20-year period were retrospectively-prospectively examined. Total duration of therapy and drug retention until the end of follow-up were calculated, as well as the reasons of discontinuation, including adverse events. Clinical response, expressed as changes in BDCAF (Beh\u00e7et\u2019s Disease Current Activity Form) indexacross the follow-up period, were evaluated and compared among patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty patients with BS were treated with IFX over a 20-year period. Overall drug retention was 45%, with survival rates of 78.3% at 1 year, 63.3% at 2 years, and 35% at 5 years (median duration 37 months, IQR 17\u201372). Most discontinuations occurred after 24 months and were mainly due to loss of efficacy (25%), de novo manifestations (21%), or allergic reactions (18%). Clinical activity improved markedly, with a mean BDCAF reduction of 4 points, ranging from \u22123.0 in mild to \u22125.7 in highly active disease. Continuers showed lower BDCAF scores at last follow-up and achieved higher remission and major response rates compared with discontinuers. Younger age and female sex were associated with higher discontinuation risk. Over the two decades, IFX indications shifted from major-organ involvement to predominantly refractory muco-cutaneous disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IFX showed good safety profile and excellent clinical response in this real-world BS cohort, with a drug survival of 45% within a median treatment duration of 37 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1726690","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:22Z","timestamp":1765175362000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A 20-year real-world study on drug survival and predictive factors for infliximab discontinuation in Beh\u00e7et\u2019s syndrome"],"prefix":"10.3389","volume":"16","author":[{"given":"Rosaria","family":"Talarico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Sulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Di Cianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Marinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02629-6","article-title":"Beh\u00e7et\u2019s syndrome","volume":"403","author":"Emmi","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.208","article-title":"Beh\u00e7et syndrome: a contemporary view","volume":"14","author":"Yazici","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-023-01593-8","article-title":"A cost-of-illness study of Beh\u00e7et syndrome in Italy","volume":"25","author":"Lorenzoni","year":"2024","journal-title":"Eur J Health Econ"},{"key":"B4","article-title":"Beh\u00e7et\u2019s syndrome and psychiatric involvement: is it a primary or secondary feature of the disease","volume":"36","author":"Talarico","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.06.019","article-title":"Ocular inflammation in beh\u00e7et disease: incidence of ocular complications and of loss of visual acuity","volume":"146","author":"Ka\u00e7maz","year":"2008","journal-title":"Am J Ophthalmology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-012-8319-x","article-title":"Beh\u00e7et syndrome: is it one condition","volume":"43","author":"Yazici","year":"2012","journal-title":"Clinic Rev Allerg Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02830","article-title":"Treating the different phenotypes of beh\u00e7et\u2019s syndrome","volume":"10","author":"Bettiol","year":"2019","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0002-9343(01)01048-8","article-title":"Vascular involvement in Beh\u00e7et\u2019s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin","volume":"112","author":"Espinosa","year":"2002","journal-title":"Am J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"109682","DOI":"10.1016\/j.clim.2023.109682","article-title":"Infliximab for vascular involvement in Beh\u00e7et\u2019s syndrome","volume":"253","author":"Hatemi","year":"2023","journal-title":"Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-017-1691-z","article-title":"Quality of life impairment in Beh\u00e7et\u2019s disease and relationship with disease activity: a prospective study","volume":"12","author":"Fabiani","year":"2017","journal-title":"Intern Emerg Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/sian1b","article-title":"Assessing quality of life in Beh\u00e7et\u2019s disease: a systematic review","volume":"40","author":"Mastrolia","year":"2022","journal-title":"ClinExpRheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-023-02668-8","article-title":"Exploring disease perception in Beh\u00e7et\u2019s syndrome: combining a quantitative and a qualitative study based on a narrative medicine approach","volume":"18","author":"Marinello","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/bk6lc0","article-title":"The impact of environmental factors on aetiopathogenesis and clinical manifestations of Beh\u00e7et\u2019s syndrome","volume":"42","author":"Di Cianni","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-24131-5","volume-title":"Beh\u00e7et Syndrome","author":"Yazici","year":"2020"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.12.006","article-title":"Beh\u00e7et\u2019s disease: New insights into pathophysiology, clinical features and treatment options","volume":"17","author":"Greco","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01085","article-title":"Beh\u00e7et\u2019s syndrome as a model of thrombo-inflammation: the role of neutrophils","volume":"10","author":"Emmi","year":"2019","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.suppl_2.ii51","article-title":"Beh\u00e7et\u2019s disease: a new target for anti-tumour necrosis factor treatment","author":"Sfikakis","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem101","article-title":"Long-term efficacy of infliximab in refractory posterior uveitis of Behcet\u2019s disease: a 24-month follow-up study","volume":"46","author":"Niccoli","year":"2007","journal-title":"Rheumatol (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-006-0425-y","article-title":"Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et\u2019s disease","volume":"51","author":"Accorinti","year":"2007","journal-title":"Jpn J Ophthalmol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-07118-9","article-title":"Long-term outcomes of infliximab treatment in neuro-Behcet syndrome: A single-center retrospective study","volume":"43","author":"Rabia","year":"2024","journal-title":"ClinRheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1391297","article-title":"Ten-year retention rate of infliximab in patients with beh\u00e7et\u2019s disease-related uveitis","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02993-9","article-title":"Real-world safety and effectiveness of infliximab in 255 patients with intestinal, neurological, and vascular beh\u00e7et\u2019s disease: A post-marketing surveillance","volume":"41","author":"Hibi","year":"2024","journal-title":"AdvTher"},{"key":"B25","doi-asserted-by":"publisher","first-page":"ard","DOI":"10.1136\/ard-2024-226113","article-title":"Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Beh\u00e7et\u2019s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial","volume":"17","author":"Talarico","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3000605231169895","DOI":"10.1177\/03000605231169895","article-title":"The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Beh\u00e7et\u2019s disease: a systematic review and meta-analysis","volume":"51","author":"Mohammed","year":"2023","journal-title":"J Int Med Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B28","article-title":"Criteria for diagnosis of Beh\u00e7et\u2019s disease. International Study Group for Beh\u00e7et\u2019s Disease","volume":"335","year":"1990","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1726690\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:23Z","timestamp":1765175363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1726690\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2025.1726690"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1726690","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"article-number":"1726690"}}